Future Oncol. 2010;6(5):665-679. Three Phase I studies by O'Donnell and colleagues have reported the pharmacodynamic activity of abiraterone acetate, which was originally developed as an oral ...

With the development of the newer agents, abiraterone acetate and enzalutamide, efforts have been made to better define the basis for response and resistance. This work can be carried out in cell ...

Abiraterone acetate plus prednisone and enzalutamide improve overall survival (OS) and radiological progression-free survival (rPFS) in docetaxel-pretreated patients. Abiraterone acetate plus ...